Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Myeloid Therapeutics
Incyte Corporation
Daiichi Sankyo
Tempest Therapeutics
Fate Therapeutics
Nektar Therapeutics
Incyte Corporation
Duke University
MultiVir, Inc.